New research shows that in countries with higher contraceptive pill use by women, men have higher rates of prostate cancer.
Although the research is speculative and causality cannot be identified, the authors suggest that use of the pill could lead to higher levels of excreted estrogen in the environment, affecting the hormone balance of the larger population.
According to the 2007 World Health Organisation data used in the analysis, 20.5% of Kiwi women in a heterosexual relationship use the pill, well above the world average of 8.5%. The paper is published in BMJ Open. Registered journalists can log into the SMC Resource Library to access the research.
Our colleagues at the UK Science Media Centre in association with Before the Headlines, have produced this easy to follow statistical review of the paper, as well as some reaction from a UK-based expert.
|Title, Date of Publication & Journal|
|Oral contraceptive use is associated with prostate cancer: an ecological study, BMJ Open, 15th November 2011|
|To examine association between prostate cancer (PCa) incidence and mortality and oral contraceptive use.|
|An ecological study comparing population levels of oral contraceptive use and PCa incidence and mortality. Data from 87 nations were included with an aim to include equal representation from developed and under-developed countries.|
|Authors used age-standardised rates of prostate cancer from the International Agency for Research on Cancer and contraceptive use data from the United Nations World Contraceptive Use report. A Pearson correlation and multivariate linear regression were used to associate the use of difference methods of contraception to prostate cancer incidence and mortality. Analyses performed by nation and worldwide. The multivariate analysis adjusted for the nations GDP due to its likely confounding effect.|
|OC use was significantly associated with PCa incidence and mortality in individual nations worldwide. PCa incidence was also associated with OC use in Europe and by continent but PCa mortality was not associated with OC use in Europe or by continent. No significant associations between PCa and use of condoms, IUD or vaginal barrier methods of contraception were found. The results for condom or IUD use were not as consistent across the different analyses as those for OC use and vaginal barrier method.|
|This was a large study using appropriate methods and analysis to look at this association at a population level.The authors aimed to include an equal representation of developed and under-developed countries and also controlled for the nation’s GDP which was very important as it is already known that countries with higher standards of living have higher rates of PCa and also have more PCa screening.The discussion of the results is well written and it is made clear that no causal relationship can be inferred from these results and that they should be considered hypothesis generating.|
|This type of study design cannot show a causal link between OC use and incidence or mortality of PCa.Data are from reports which are based on survey and registry data which is unlikely to have been reported consistently accurately across nations.Other methods of contraception and nations GDP were the only two confounders included in the analyses although the authors are quite clear in the discussion that ‘additional confounding does exist’.|
|Conclusions of the Paper|
|The discussion highlights a few plausible explanations for this which should be investigated further. These include the fact that PCa has been associated with sexual transmission but that the results for the different methods of contraception in this study do not really support that conclusion. The authors discuss other recent research that both support and contradict the results of this study. They also point out that the true levels of Endocrine Disrupting Compounds (EDC) in the water supply and food is not available, but hope that it will be in the future – this will be the key data to help support or refute the results from this study. The fact that the association is seen in the incidence of PCa but not consistently in the mortality from PCa is not discussed.|
Dr Kate Holmes, Research Manager at The Prostate Cancer Charity, UK, comments:
“This study does not present a strong evidence case for an association between the use of the contraceptive pill and prostate cancer, nor does it intend to. It is intended to explore the possibility that release of endocrine disruptive chemicals (EDCs) into the environment, a process which is not unique to the pill, might impact on the incidence of the disease. However, for all of the 87 countries in the study, there is no information on the level of these chemicals in the environment, with the focus on the contraceptive pill as the sole source, which we know is not the case.
“Other types of contraceptive use are investigated too, to rule out the potential that increased levels of sexual activity are related to prostate cancer, or that a sexually transmitted infection could be linked to the disease. However, it would not be a surprise that countries which have a higher use of the contraceptive pill also have a higher detection level of prostate cancer, as this would be a reflection of a higher quality health care system in that country.
“While this study raises some interesting questions about the presence of EDCs in the environment, it does not contribute to our overall understanding of the development of prostate cancer.”